| 2005 |
NHE7 (SLC9A7) resides chiefly in the trans-Golgi network (TGN) and post-Golgi vesicles, and its cytoplasmic C-terminus directly interacts with SCAMP2 (and also SCAMP1 and SCAMP5) via the TM2-TM3 cytoplasmic loop of SCAMP2. This interaction regulates NHE7 trafficking between the TGN and recycling vesicles; disruption of the binding interface (SCAMP2 deletion mutant lacking residues 184-208 or a GFP-TM2-TM3 construct) causes redistribution of NHE7 to scattered recycling vesicles without affecting other TGN/Golgi markers. |
Yeast two-hybrid screen, co-immunolocalization, co-immunoprecipitation, sucrose density gradient co-sedimentation, in vitro protein binding assays, dominant-negative/deletion mutant overexpression |
Journal of cell science |
High |
15840657
|
| 2006 |
Caveolins directly bind to the C-terminal extension of NHE7 via an unconventional binding module. NHE7 associates with caveolae/lipid raft fractions dependent on this C-terminal extension and on cholesterol; a deletion mutant lacking the C-terminal extension is excluded from caveolae/lipid rafts. NHE7 endocytosis proceeds via clathrin-dependent (not caveolar) mechanisms, as pharmacological blockade of clathrin-dependent endocytosis inhibits NHE7 internalization while dominant-negative caveolin or methyl-β-cyclodextrin does not. |
Co-immunoprecipitation, lipid raft fractionation, dominant-negative caveolin mutants, cholesterol-depleting drugs, deletion mutagenesis, endocytosis inhibition assays |
Cellular signalling |
High |
17207967
|
| 2008 |
Mass spectrometry-based interactome analysis of affinity-captured NHE7 identified cytoskeletal proteins, cell adhesion molecules, membrane transporters, and signaling molecules as binding partners. Among these: (1) calcium-calmodulin (but not apo-calmodulin) binds NHE7 and regulates its organellar transporter activity; (2) vimentin co-immunoprecipitates with endogenous NHE7 and colocalizes with NHE7 at focal complexes in migrating cells; (3) CD44 shows regulated interaction with NHE7 that is enhanced by phorbol ester treatment and dependent on lipid raft integrity. |
Affinity capture mass spectrometry, co-immunoprecipitation, co-immunolocalization, phorbol ester treatment, lipid raft disruption |
Molecular membrane biology |
Medium |
18654930
|
| 2014 |
NHE7 transports Li+ and Na+, but not K+, and functions as a proton-loading (acidifying) transporter rather than a proton leak/alkalinizer. It is constitutively activated by cytosolic H+ and is non-reversible under physiological conditions. NHE7-mediated vesicular acidification is additive to that of V-ATPases and accelerates endocytosis. These transport parameters were established by selecting a cell line expressing wild-type NHE7 at the plasma membrane via proton-killing techniques, enabling direct functional measurements. |
Proton-killing selection of plasma-membrane NHE7-expressing cells, ion transport assays with Li+/Na+/K+ substitution, pH measurements, endocytosis assays, pharmacological inhibition of V-ATPase |
Cell reports |
High |
24767989
|
| 2019 |
A gain-of-function missense variant (Leu515Phe) in SLC9A7 causes alkalinization of TGN/post-Golgi compartments, which impairs N-linked oligosaccharide maturation of both NHE7 itself and a co-transfected secretory glycoprotein (VSVG), while membrane trafficking to the cell surface remains relatively unaffected. Patient serum shows abnormal N-glycosylation of transferrin by mass spectrometry, establishing SLC9A7/NHE7 as a regulator of TGN/post-Golgi pH homeostasis required for proper glycosylation of exported cargo. |
Transfection of CHO AP-1 cells with wild-type vs. Leu515Phe mutant NHE7, organellar pH measurement, N-glycosylation assays, VSVG trafficking assay, patient serum mass spectrometry |
Human molecular genetics |
High |
30335141
|
| 2020 |
NHE7 acidifies the Golgi lumen, and NHE7 suppression causes alkalinization of the Golgi leading to a buildup of cytosolic acid. This disruption of cytosolic pH homeostasis acts primarily through dysregulation of actin, compromising pancreatic cancer cell fitness and abolishing tumor growth in vivo. |
NHE7 knockdown (siRNA/shRNA), organellar and cytosolic pH measurements (biosensors), actin cytoskeleton analysis, in vivo xenograft tumor growth assays |
Cancer discovery |
High |
32200349
|
| 2023 |
NHE7 alkalized intracellular (cytosolic) pH and acidified endosomal pH, promoting maturation of macropinosomes and thereby enhancing uptake of small extracellular vesicles (sEVs) via macropinocytosis in hepatocellular carcinoma cells. Inducible NHE7 inhibition in established tumors delayed tumor development and suppressed lung metastasis. |
NHE7 knockdown and overexpression, pH biosensor measurement, dextran/sEV internalization assays, EIPA pharmacological inhibition, inducible in vivo silencing |
Cancer communications |
Medium |
38152992
|
| 2025 |
NHE7 binds to a cAMP-related transcription factor (CREB), increasing GRIN2B expression and thereby elevating intracellular Ca2+ influx, which delays cellular senescence and promotes endometrial cancer progression in vitro and in vivo. |
Co-immunoprecipitation/binding assays, RNA-seq, overexpression and knockdown functional assays, xenograft mouse model, Ca2+ measurement |
Communications biology |
Low |
40473875
|
| 2026 |
In macrophages, lactate-induced lactylation of Histone 3 at the DNMT1 promoter activates DNMT1 transcription, which then silences NHE7 gene expression. NHE7 downregulation in macrophages drives M2 polarization and senescence through MAPK pathway activation, promoting endometrial cancer progression. |
ChIP for histone lactylation, RT-qPCR, western blotting, NHE7 overexpression in macrophages, xenograft tumor model |
Cell death & disease |
Low |
41617670
|
| 2011 |
NHE7 dynamically shuttles between the TGN, endosomes, and the plasma membrane, and regulates the luminal pH of these organelles. NHE7 overexpression in breast cancer MDA-MB-231 cells enhances cell-cell adhesion, invasion, anchorage-independent growth, and in vivo tumor formation, distinct from NHE1 overexpression effects. |
NHE7 overexpression, in vitro invasion and adhesion assays, anchorage-independent growth assay, in vivo xenograft tumor formation |
Oncology reports |
Medium |
22076128
|